This Month
Singapore contract manufacturer lands at PE-backed Aussie medtech
Singapore-based contract manufacturer Meiban Group has taken a 20 per cent stake in Planet Innovation.
CSL prepares to slash R&D as it grapples with looming Trump tariffs
The market is focused on a mooted 200 per cent levy on the pharmaceutical giant’s goods. There are far more significant changes afoot at the company.
Target hostile countries, not us, drug giant CSL tells Trump
The country’s biggest pharmaceuticals group pointed to “specific non-allied countries” and urged the White House to reconsider a 200 per cent tariff.
Sick of doctor fee gouging? Don’t ask government to fix it
Government reluctance to intervene in the medical profession means we must consider reform based on market forces to empower consumers.
June
Rich Australians are paying $3500 for this scan
Rebecca Keen believes a full-body MRI may have saved her life, but doctors say getting one could cause more harm than good.
‘Game changer’ diabetes pill a step closer after trials
Diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments such as Ozempic.
‘Next Cochlear’ launches ASX float to sell its ‘medical Lego’
Tetratherix, a medical device company backed by Xero founder Rod Drury, is set to make its ASX debut later this month with an ambitious global pitch for investors.
May
‘Game changer’ Alzheimer’s blood test cleared in the US
US regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find and treat patients.
Disclosure doozy makes a mockery of Australia’s safe-haven fantasy
If you told a private-equity suitor about a regulatory headache, but not shareholders, was the event disclosable or not? A 15 per cent share price drop says Mayne Pharma got this one wrong.
The companies that are winners and losers from Labor’s landslide victory
Winners include healthcare diagnostics, vehicle financiers, and developers. Mortgage insurers, fuel suppliers, and automotive firms may face challenges.
The stage of life Australians can’t afford to ignore
Kate Carnell says federal funds for end-of-life planning would reduce costly hospitalisations and prevent unnecessary suffering.
The Aussie bringing Black Mirror-esque brain tech to reality
This neurologist has built technology allowing humans to control machines with just their thoughts. Now he’s racing Tesla’s founder to take it to the masses.
April
Pharmacy Guild coming to you from the Chairman’s Lounge
Labor has been remarkably kind to the chemists’ lobby group recently, but we suspect that’s more due to their choice of lobbyist than airline lounge access.
This $1.3b biotech is still run out of a spare bedroom in Melbourne
It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump. Now it has a promising new drug.
Meet the 24-year-old Australian behind a $300m US start-up
Max Marchione moved to San Francisco to start Superpower and capitalise on the US’ under-resourced healthcare sector.
Eli Lilly issues warning for Australia as Trump signals pharma tariffs
In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.
Doctors say this show is first to get the emergency ward right
Binge’s unusually accurate medical drama The Pitt, starring Noah Wyle as a beleaguered intensive care physician, has become the talk of real-life hospital breakrooms.
Woolworths buys into telehealth consultations with $70m start-up
The supermarket giant’s pharmacy division has led a funding round in Hola Health, giving customers access to virtual doctor’s appointments and prescriptions.
March
How Ozempic and other GLP-1s are transforming much more than just waistlines
We don’t yet know how many Australians are taking the jab, but we’re certainly seeing the effects.
Doctors told him he was going to die. Then AI saved his life
In labs around the world, scientists are using AI to search among existing medicines for treatments that work for rare diseases.